Opinion statement Corticosteroids have been used in the management of prostate cancer for
over 30 years. Although daily oral corticosteroids have frequently used in conjunction with …

Extensive clinical development in metastatic castrate-resistant prostate cancer (mCRPC)
has led to the introduction of three new agents in little more than a year, with more on the …

Background Abiraterone acetate has been approved for metastatic castration-resistant
prostate cancer (mCRPC). Coadministration with prednisone has been recommended to …

Corticosteroids have been used in combination with chemotherapy for the treatment of
metastatic castration-resistant prostate cancer (mCRPC) for more than three decades …

Background Corticosteroids have been used to mitigate mineralocorticoid-related effects
and restore sensitivity to abiraterone acetate. Corticosteroids may also mediate …

Abiraterone acetate, a prodrug of the CYP17A1 inhibitor abiraterone that blocks androgen
biosynthesis, is approved for treatment of patients with metastatic castration-resistant …

Importance Abiraterone acetate is combined with prednisone, 5 mg, twice daily for
metastatic castration-resistant prostate cancer (mCRPC) and with prednisone, 5 mg, once …

Purpose: The clinical impact of concurrent corticosteroid use (CCU) on enzalutamide-treated
patients with metastatic castration-resistant prostate cancer (mCRPC) is unknown. We …

Context The development of agents targeting androgen signalling holds promise for men
with castration-resistant prostate cancer (CRPC). Objective The emerging role of abiraterone …

Great strides have been made in the treatment of castration-resistant prostate cancer
(CRPC) with the development of new antiandrogens (enzalutamide) and more potent …